2A Pharma

2A Pharma is a Swedish/Danish biopharmaceuticals company founded in 2016, specializing in the discovery, development, and commercialization of novel, cost-effective prophylactic and therapeutic vaccines. Their lead vaccine candidate, 2AP07, is a therapeutic cancer vaccine targeting adenocarcinomas expressing EpCAM. Utilizing adeno-associated virus-like particles (AAVLPs), 2A Pharma's technology enables the production of highly efficient vaccines without the need for adjuvants. This innovative approach leverages the immune system to generate highly effective antibodies with selected specificities and functions. Based in Malmö, Sweden, 2A Pharma employs 11 individuals and operates as a privately held company.

The company's vaccine technology is based on AAVLPs, which assemble viral capsids without containing viral genomes, making them replicative-defective and non-pathogenic. These viral capsids have repetitive immunogenic sites that can be modified to encompass antigenic epitopes for a protein of interest, activating both the innate and adaptive immune systems. This technology provides significant competitive advantages in vaccine production.

2A Pharma's mission is to exploit the efficacy of the immune system to generate highly effective vaccines, offering a promising solution for cancer treatment and other therapeutic areas. Their innovative approach and focus on cost-effective vaccine production make them a valuable player in the biopharmaceuticals industry.